Atreca (BCEL) is scheduled to report 4th quarter earnings on 03/13/2024.
Regarding Q4 estimates, Wall Street analysts expect Atreca to post earnings of -$0.35 per share. Last quarter, Atreca missed earnings estimates, reporting EPS of -$0.92 on estimates of -$0.38. The stock fell by -23.08% the day after the last earnings release.
Year-to-date, BCEL stock has risen by 72.23%.
About Atreca
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.
Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.
